| Targets | Partner | Discovery | Preclincal | Phase 1 | Phase 2 | ||
PRS-346/SGN-BB228 |
4-1BB/CD288 |  |
✓ | ✓ | ✓ | Learn More | |
PRS-342/BOS-342 |
4-1BB/GPC3 |  |
✓ | ✓ | ✓ | Learn More | |
Candidate Seagen Programs‡ |
n.d. | |
✓ | Learn More |
Focused Solutions for Oncology
Pieris Pharmaceuticals is proud to partner with industry leaders in immuno-oncology. Read how these key partnerships are helping us produce superior outcomes for patients.
Immuno-Oncology
‡ 2 active bispecific programs in collaboration with Pfizer in addition to PRS-346/SGN-BB228 listed above
‡ 2 active bispecific programs in collaboration with Pfizer in addition to PRS-346/SGN-BB228 listed above
Candidate
PRS-346/SGN-BB228
TARGETS
4-1BB/CD228
PARTNER
PHASE 1
In Progress
Candidate
Candidate Seagen Programs‡
TARGETS
n.d.
PARTNER
DISCOVERY
In Progress